Opendata, web and dolomites


PlateLys: The innovative human platelet lysate especially designed to maximize the effectiveness of cell-based therapies

Total Cost €


EC-Contrib. €






 PLATELYS project word cloud

Explore the words cloud of the PLATELYS project. It provides you a very rough idea of what is the project "PLATELYS" about.

flexibility    2017    combining    patient    fda    date    negatives    vitro    lethal    powder    native    solution    standardized    species    300    therapies    thanks    remarkable    leverage    sera    winning    substantial    inactivated    animal    stem    hpl    previously    complete    seek    starting    award    commercialization    isolated    patented    operators    approved    reactions    inhumanely    platome    point    mimic    ongoing    14    fast    formulation    platelet    cow    million    maximal    implanted    founders    immune    52    expand    disease    supplements    fetuses    gmp    cellular    worth    2021    unprecedented    cagr    viral    quality       profile    grade    serum    engineered    acute    indispensable    certified    environment    tissue    patients    endanger    nonviable    lysate    2016    ups    clinical    staff    safety    calf    collect    turnover    source    lysates    sacrificed    start    therapeutic    oriented    mad    optimization    substitute    borne    cell    culture    transmission    portfolio    platelys    cultured    highest    billion    shift    created    market    fulfilling    human    cells    hormones    2025    area    cross    amenable    period    leads    icelandic    diseases   

Project "PLATELYS" data sheet

The following table provides information about the project.


Organization address
address: ALFASKEIDI 27
postcode: 220
website: n.a.

contact info
title: n.a.
name: n.a.
surname: n.a.
function: n.a.
email: n.a.
telephone: n.a.
fax: n.a.

 Coordinator Country Iceland [IS]
 Project website
 Total cost 71˙429 €
 EC max contribution 50˙000 € (70%)
 Programme 1. H2020-EU.3. (PRIORITY 'Societal challenges)
2. H2020-EU.2.3. (INDUSTRIAL LEADERSHIP - Innovation In SMEs)
3. H2020-EU.2.1. (INDUSTRIAL LEADERSHIP - Leadership in enabling and industrial technologies)
 Code Call H2020-SMEInst-2018-2020-1
 Funding Scheme SME-1
 Starting year 2018
 Duration (year-month-day) from 2018-08-01   to  2018-11-30


Take a look of project's partnership.

# participants  country  role  EC contrib. [€] 


 Project objective

Cellular therapies making use of stem cells, engineered immune cells or engineered tissue represent an unprecedented and fast-growing therapeutic area. To date, 14 cell therapies have been approved by the FDA. However, the cells being implanted to the patient need to be cultured in vitro at some point under highly specific and controlled conditions. One of these conditions –indispensable to culture any type of isolated cell in vitro– involves using animal-derived serum as a source of hormones and growth factors to mimic cells' native environment. It is estimated 1.5 million calf fetuses are inhumanely sacrificed to collect serum. This leads (among other negatives) to endanger patient's safety, because of cross-species immune reactions (which may be lethal) and the transmission of animal borne diseases (e.g. the mad cow disease). PlateLys is PLATOME´s solution to develop and produce a remarkable human-based serum substitute fulfilling all the requirements to culture cells. PLATOME is an award-winning Icelandic start-up created in 2016 to leverage the substantial know-how on human platelet lysates (hPL) production from its founders. PlateLys is the only hPL combining: a viral-inactivated hPL ensuring the highest safety profile for patients and operators; a clinical-grade lysate with standardized quality control and GMP certified amenable for research and clinical set-ups; a powder formulation providing maximal flexibility, especially on applications that were nonviable previously. The market of sera supplements will be worth €1.14 billion by 2025 (CAGR of 8%, period 2017-2025) with a large shift to hPL use ongoing. Through the PlateLys project we seek to complete the optimization and scale-up production, starting commercialization activities in Europe by 2021. By 2025, we will have generated €5.52 million in turnover and increase our staff by 300%. PlateLys will allow us to expand our portfolio of cell-oriented products, thanks to our patented production technology.

Are you the coordinator (or a participant) of this project? Plaese send me more information about the "PLATELYS" project.

For instance: the website url (it has not provided by EU-opendata yet), the logo, a more detailed description of the project (in plain text as a rtf file or a word file), some pictures (as picture files, not embedded into any word file), twitter account, linkedin page, etc.

Send me an  email ( and I put them in your project's page as son as possible.

Thanks. And then put a link of this page into your project's website.

The information about "PLATELYS" are provided by the European Opendata Portal: CORDIS opendata.

More projects from the same programme (H2020-EU.3.;H2020-EU.2.3.;H2020-EU.2.1.)

MCBD (2019)


Read More  

In-Heal (2019)

Standardised administration device for raw medical herbs

Read More  

SQP (2019)

Opening new markets for Single Quantum Photodetectors

Read More